Zeria Pharmaceutical Co., Ltd. (TYO:4559)

Zeria Pharmaceutical Ratios and Metrics

Market cap in millions JPY. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 20, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	91,112	99,488	93,978	98,960	85,331	96,124
Market Cap Growth	-14.09%	5.86%	-5.03%	15.97%	-11.23%	-0.78%
Enterprise Value	108,439	119,281	125,376	134,397	126,409	124,464
Last Close Price	2067.00	2231.24	2064.91	2131.85	1774.45	1926.45
PE Ratio	16.24	10.01	12.16	15.97	21.54	30.82
Forward PE	11.11	10.13	11.34	12.53	20.60	28.59
PS Ratio	1.07	1.14	1.24	1.45	1.43	1.73
PB Ratio	0.99	1.11	1.18	1.51	1.55	1.71
P/TBV Ratio	1.73	2.02	2.58	4.21	6.23	6.90
P/FCF Ratio	16.13	8.66	10.12	9.20	10.82	15.60
P/OCF Ratio	11.96	7.70	7.71	7.52	9.53	13.94
EV/Sales Ratio	1.28	1.37	1.66	1.97	2.12	2.25
EV/EBITDA Ratio	6.60	6.04	7.30	8.86	10.74	15.80
EV/EBIT Ratio	11.91	9.78	13.03	14.91	19.86	36.15
EV/FCF Ratio	19.20	10.38	13.51	12.49	16.03	20.20
Debt / Equity Ratio	0.43	0.46	0.58	0.75	0.95	0.89
Debt / EBITDA Ratio	2.38	2.08	2.69	3.26	4.44	6.34
Debt / FCF Ratio	7.05	3.58	4.98	4.60	6.62	8.11
Asset Turnover	0.54	0.56	0.53	0.53	0.48	0.49
Inventory Turnover	1.33	1.51	1.48	1.53	1.51	1.53
Quick Ratio	0.89	0.92	0.76	0.71	0.63	0.43
Current Ratio	1.31	1.28	1.06	1.02	0.94	0.69
Return on Equity (ROE)	6.08%	11.75%	10.58%	10.28%	7.14%	5.75%
Return on Assets (ROA)	3.70%	4.92%	4.21%	4.35%	3.23%	1.90%
Return on Invested Capital (ROIC)	4.46%	5.93%	4.99%	5.07%	3.73%	2.22%
Return on Capital Employed (ROCE)	8.90%	11.60%	10.00%	10.30%	7.90%	5.10%
Earnings Yield	6.16%	9.99%	8.23%	6.26%	4.64%	3.25%
FCF Yield	6.20%	11.55%	9.88%	10.87%	9.24%	6.41%
Dividend Yield	2.32%	2.11%	2.13%	1.88%	1.97%	1.76%
Payout Ratio	37.70%	19.89%	25.03%	25.67%	38.83%	50.27%
Buyback Yield / Dilution	0.00%	0.00%	0.21%	2.14%	2.02%	1.38%
Total Shareholder Return	2.31%	2.11%	2.34%	4.01%	4.00%	3.14%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.